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Prior evidence has supported the existence of multiple susceptibility genes for schizophrenia. Multipoint linkage
analysis of the 270 Irish high-density pedigrees that we have studied, as well as results from several other samples,
suggest that at least one such gene is located in region 6p24-21. In the present study, family-based association
analysis of 36 simple sequence-length–polymorphism markers and of 17 SNP markers implicated two regions,
separated by ∼7 Mb. The first region, and the focus of this report, is 6p22.3. In this region, single-nucleotide
polymorphisms within the 140-kb gene DTNBP1 (dystrobrevin-binding protein 1, or dysbindin) are strongly as-
sociated with schizophrenia. Uncorrected, empirical P values produced by the program TRANSMIT were significant
( ) for a number of individual SNP markers, and most remained significant when the data were restricted toP ! .01
include only one affected offspring per nuclear family per extended pedigree; multiple three-marker haplotypes
were highly significant ( ) under the restricted conditions. The pattern of linkage disequilibrium isPp .008–.0001
consistent with the presence of more than one susceptibility allele, but this important issue is unresolved. The
number of markers tested in the adjacent genes, all of which are negative, is not sufficient to rule out the possibility
that the dysbindin gene is not the actual susceptibility gene, but this possibility appears to be very unlikely. We
conclude that further investigation of dysbindin is warranted.
Introduction
Although genetic factors are known to be important in
the etiology of schizophrenia (Gottesman and Shields
1982; Kendler 2000), unambiguous identification of the
important susceptibility genes for this common and de-
bilitating condition has not yet been accomplished. Var-
ious causes for this barrier to progress, both established
and speculated, have been amply discussed, and, in rec-
ognition of the magnitude of the problem, improvements
on various fronts have been initiated; these include (a)
dramatic expansion of sample sizes by inclusion of triad
and case-control studies and (b) a renewed emphasis on
additional biologically based intermediate phenotypes.
As has been detailed in dozens of extensive reviews
(Karayiorgou and Gogos 1997; Tsuang et al. 1999; Ri-
ley and McGuffin 2000; Baron 2001; Bray and Owen
2001), after several well-publicized false leads, many
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plausible candidate regions for schizophrenia are now
under intense scrutiny; these include regions 1q21-22,
1q32-42, 5q21-34, 6p24-21, 6q13-26, 8p22-21, 10p15-
11, 13q14-32, 15q13-15, and 22q11-13. After the in-
itial reports (Straub et al. 1995; Wang et al. 1995),
chromosome 6p (locus SCZD3 [MIM 600511]) has had
support from a number of follow-up studies, withmark-
ers in a variety of locations showing at least some degree
of positive evidence. It has been difficult, though, to
distinguish true positives from false positives, because
of the large number of markers tested under many ge-
netic and phenotypic models using many samples, most
of which were only of moderate size, that were ascer-
tained under different conditions. In addition, it is still
not clear to what extent (if any) a positive marker or
multipoint peak 120 cM from the original should be
interpreted as a “replication.” Statistical significance
alone is clearly neither a sufficient nor a particularly
well-chosen metric (Morton 1998), since (1) very sig-
nificant results (e.g., a heterogeneity LOD score [H-
LOD] 14) are not necessarily true and (2) supposedly
weaker results (e.g., H-LOD 1.5–3) have led to gene
identification and so must not be prematurely dis-
counted. Independent replication attempts, although
theoretically a powerful tool, are actually only rarely
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performed, because of numerous inherent and funda-
mental differences between studies (Straub et al. 1996;
Vieland 2001).
On 6p, the markers positive for schizophrenia are
distributed widely over the 25Mb between D6S296 and
D6S291. They do appear, however, to be concentrated
within four subregions: 6p25-24, near D6S296/D6S309
(Antonarakis et al. 1995; Maziade et al. 1997, 2001;
Hovatta et al. 1998; Lindholm et al. 1999; Bailer et al.
2000; Hwu et al. 2000); 6p24, near D6S940/D6S470
(Schizophrenia Linkage Collaborative Group for Chro-
mosomes 3, 6 and 8 1996); 6p23-22, near D6S260 (Tur-
ecki et al. 1997; Hovatta et al. 1998; Hwu et al. 2000);
and 6p21, both proximal to (Arolt et al. 1996) and
within (Wright et al. 2001) the locus for human leu-
kocyte antigen. The sample studied by Schwab et al.
(1995) shows positive markers and multiple multipoint
peaks from 6p24 through 6p21 (Schwab et al. 2000),
as does the Irish high-density sample that we have stud-
ied. In addition, there have been association studies of
SCA1 (on 6p22) (Wang et al. 1996; Pujana et al. 1997;
Joo et al. 1999) and of NOTCH4 (Wei and Hemmings
2000; Imai et al. 2001; McGinnis et al. 2001; Sklar et
al. 2001; Ujike et al. 2001).
In two previous reports from the Irish Study of High
Density Schizophrenia Families (ISHDSF), we have pre-
sented evidence in support of the linkage of region 6p24-
21 to schizophrenia and schizophrenia-related disorders
(Straub et al. 1995, 2002). In the present study, we
describe the results of family-based association analysis
of simple sequence-length polymorphism (SSLP) mark-
ers, additional genotyping of SNPs in 6p22, and analysis
of SNP haplotypes. We find that genetic variation in the
gene for DTNBP1, which is the human ortholog of
mouse dysbindin, is associated with schizophrenia and
related phenotypes.
Subjects and Methods
Pedigree Ascertainment and Diagnostic Assessment
A detailed description of the ISHDSF has been pub-
lished elsewhere (Kendler et al. 1996). The sample used
here contains 270 families and 1,425 genotyped indi-
viduals (Straub et al. 2002). The main diagnostic in-
struments utilized in the fieldwork were the Structured
Interview for DSM-III-R Diagnosis (Spitzer et al. 1992)
and the Structured Interview for Schizotypy (Kendler et
al. 1989). Diagnosis was based on DSM-III-R criteria
and all available information (personal history, hospital
record, and family-history report), by individuals blind
to knowledge of genotypes and to psychopathology of
relatives. This research was approved by the Ethical Re-
view Boards of Virginia Commonwealth University, the
Health Research Board (Dublin), andQueen’s University
(Belfast). The diagnostic definitions are as follows.
Narrow: categories D1–D2 (625 affected individuals,
565 of whom were genotyped).—These categories com-
prise the “core schizophrenic phenotypes,” which include
schizophrenia, poor-outcome schizoaffectivedisorder,and
simple schizophrenia (Kendler et al. 1994).
Intermediate: categories D1–D5 (804 affected individ-
uals, 691 of whom were genotyped).—These catego-
ries comprise a restricted definition of the schizophrenia
spectrum, which includes only disorders that repeatedly
have been shown to coaggregate in families with nar-
rowly defined schizophrenia (Kendler and Diehl 1993);
to the “narrow” definition, the three additional cate-
gories (i.e., D3–D5) add schizotypal personality disorder
and all other nonaffective psychotic disorders (i.e., schi-
zophreniform disorder, delusional disorder, atypical psy-
chosis, and good-outcome schizoaffective disorder).
Broad: categories D1–D8 (888 affected individuals,
744 of whom were genotyped).—These categories com-
prise a broad definition of the schizophrenia spectrum,
which includes all disorders that aggregate significantly
in relatives of schizophrenic probands in the Roscom-
mon Family Study (Kendler et al. 1993a, 1993b, 1993c),
an epidemiologic, case-controlled family study con-
ducted, in parallel, in the west of Ireland; to the “inter-
mediate” definition, the three additional categories (i.e.,
D6–D8) add mood-incongruent and mood-congruent
psychotic affective illness, and paranoid, avoidant, and
schizoid personality disorder.
Very broad: categories D1–D9 (1,172 affected individ-
uals, 952 of whom were genotyped).—These categories
comprise all psychiatric disorders; to the “broad” defi-
nition, the additional category (i.e., D9) adds all other
psychiatric disorders (e.g., nonpsychotic affective disor-
ders, anxiety disorders, alcoholism, and other non–schi-
zophrenia-spectrum personality disorders).
SNP Identification
SNPs were identified by sequencing of amplicons from
pools of 6–12 unrelated affected individuals from fam-
ilies showing a linkage signal in 6p22 but not in 6p24.
We sequenced in both directions, using ABI 377 se-
quencers (Perkin Elmer Biosystems) and dye-terminator
chemistry. Many of the novel SNPs that we discovered
were assigned NCBI reference identification numbers
(see the NCBI Single Nucleotide PolymorphismWeb site)
after being submitted to NCBI by other laboratories, and
these “rs” numbers are shown in table 2. Information
on SNP P1635 can be accessed via its NCBI “Assay ID”
(i.e., “ss” number), which is 4473786.
SNP Genotyping
The fluorescence-polarization template–directed in-
corporation method (Chen and Kwok 1999; Chen et al.
1999), which is a single-base extension with allele-spe-
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cific ddNTP termination, was used, with minor modi-
fications (Sullivan et al. 2001).
Statistical Analysis
The GENEHUNTERmultipoint methods and a graph
of the results are contained in our genome-scan report
(Straub et al. 2002). The Penetrance-Additive model is
an intermediate, heterozygotic genetic model that is ad-
ditive on the penetrance scale. For example, for the phe-
notypic model using categories D1–D2, we set AA to
0.55, Aa to 0.275, and aa to 0.0006, with a phenocopy
proportion of 0.10 and a schizophrenia-allele frequency
of 0.0098. The statistical methods used in the present
study are as follows. SIMWALK2 (Weeks et al. 1995;
Sobel and Lange 1996) was used for detection of errors
in the data. Before data cleaning, the recombinant pro-
files produced by SIMWALK haplotyping showed 72
single recombinants, 104 double recombinants, and 4
quadruple recombinants. There were 26,337 genotypes
that were checked, and SIMWALK flagged 324 recom-
binants that had a 1.25 posterior probability of being
due to genotyping error; for this group of 324 recom-
binants, the probability was 1.5 for 196 and 1.75 for
119. As a rule, only those recombinants for which the
probability is 1.90 are highly likely to be true errors, so,
to be conservative, we eliminated the 119 recombinants
(0.45% of all genotypes) having probabilities 1.75. Ver-
sion 2.5 (April 1999) of the program TRANSMIT (Clay-
ton 1999; Clayton and Jones 1999; Dudbridge et al.
2000) was used for family-based transmission/disequi-
librium test (TDT) analysis. In all TRANSMIT runs, the
program performed 100,000 replicates, and, from
these, derived the P values empirically. For both the pair-
wise analysis of SSLPs and the haplotype analysis, to
protect against misleading results due to rare alleles or
haplotypes, the command-line switches (i.e., flags) “-
agg3” and “-c3” were used to aggregate all alleles or
haplotypes with frequencies !.03 before haplotype con-
struction. For some tests, the switches “-1” and “-nomf”
were used together, to simultaneously restrict the anal-
ysis to one affected offspring per nuclear family per ex-
tended pedigree, each chosen at random by the program.
To assess the effect of the particular (random) choices
that were made, we ran each test 20 times, and we pre-
sent here the median P value. For the most significant
results, we also performed an additional 50 runs, and
the median was consistently the same as that for the
initial 20 runs. We note that, given the linkage evidence,
there is an increased a priori probability that small P
values represent true positive results. Since the markers
are tightly linked, the P values may be highly correlated,
and thus a simple Bonferroni correction is unduly con-
servative, and we report only these empirical P values
as determined by TRANSMIT. In our Irish data set, only
60 families have both parents of the largest sibship ge-
notyped, another 90 families have one parent genotyped,
and the remaining 120 families have neither parent ge-
notyped. Thus, a program such as TRANSMIT, which
is “vertical” in that it attempts to reconstruct themissing
parental information, is more powerful (see Cervino and
Hill 2000) than either (a) programs such as SIBASSOC
and STDT, which utilize only information within sib-
ships, or (b) the traditional TDT, which relies heavily
on the usually scarce heterozygous parents. The stan-
dardized (i.e., Lewontin [1988]) measure of linkage dis-
equilibrium (LD), denoted as “D′,” and the measure d2
were both calculated from the TRANSMIT haplotype
frequencies for alleles at all possible pairs of SNP loci.
MEGA2 (Mukhopadhyay et al. 1999), version 2.2, was
used to calculate allele and genotype frequencies and to
test for departure from Hardy-Weinberg equilibrium, in
affected individuals, in unaffected individuals, and in the
two groups combined.
Results
The results from GENEHUNTER multipoint analysis
(see Straub et al. 2002) of data from 36 SSLP markers
are shown in table 1. In both the H-LOD (shown) and
nonparametric linkage (NPL) (not shown) results, there
are two predominant, sharp peaks, one at ∼8 cM (in
6p24.3, near D6S940) and another at ∼17 cM (in 6p22,
near D6S260). A third peak, smaller than these two, is
present near D6S422 (in 6p22, distal to HLA). For the
two larger peaks, the H-LODs are greatest when the
broad-definition diagnostic categories (i.e., D1–D8) are
used. Whether these peaks indicate the presence of mul-
tiple susceptibility loci or are statistical artifacts could
not be determined on the basis of the linkage data alone.
In an attempt to narrow the target region(s), family-
based TDT analysis of the 36 SSLPs was performed, by
TRANSMIT (Clayton 1999; Clayton and Jones 1999;
Dudbridge et al. 2000). In the first analysis (denoted
“All”), data from all individuals in all families were used.
The second analysis, designed to mimic aspects of the
traditional TDT test, used data from only one affected
offspring per nuclear family per extended pedigree. We
did not run simple TDT or haplotype relative-risk anal-
ysis, since, for family structures such as those in the
ISHDSF, each has the considerable disadvantage of dis-
carding valuable information (Cervino and Hill 2000).
For all tests, the program generates empirical P values
by simulation. Under the first analysis (i.e., All), of the
36 SSLPs, only the 6p24.3 marker D6S940 showed a
global P value !.01. The P values were .033, .023, .016,
and .008, for diagnostic categories D1–D2, D1–D5,
D1–D8, and D1–D9, respectively. The adjacent SSLPs,
GATA23E10 (892 kb distal) and D6S470 (182 kb prox-
imal), were both negative. For D6S940, when the anal-
ysis was performed on the restricted data set without
aggregation of rare alleles, the P values were .024, .114,
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Table 1
GENEHUNTER Multipoint Linkage Results
REGION MARKER NAME LOCUS
LOCATION MULTIPOINT H-LOD
cM Mba D1–D2 D1–D5 D1–D8 D1–D9
GATA3H05 D6S477 0 7.19 .10 .55 1.12 .05
F13A1 F13A1 1.8 7.20 .15 .79 1.40 .14
D6S309 D6S309 4.9 9.28 .26 1.02 1.40 .28
D6S277 D6S277 6 9.56 .22 .99 1.44 .31
D6S263 D6S263 6.01 9.60 .33 1.20 1.50 .34
MS236 D6S226 6.02 9.64 .34 1.05 1.33 .29
D6S296F D6S296 6.03 9.91 .33 1.05 1.33 .28
D6S410 D6S410 6.33 10.05 .27 1.08 1.39 .34
6p24.3 GATA23E10 7.53 10.54 .46 1.50 1.90 .45
6p24.3 UT6077F D6S940 7.73 11.44 .43 1.29 1.69 .42
6p24.3 D6S470L D6S470 8.03 11.62 .82 1.75 2.15 .46
6p24.3 AFMc031yd9 8.04 11.68 .46 1.36 1.75 .44
ATA33A11 D6S1263 12.34 14.56 .23 .64 1.08 .31
ATA50C05 D6S2434 14.04 15.83 .33 .54 1.02 .27
D6S443 D6S443 14.34 15.87 .33 .59 1.00 .29
B337WG9L D6S1653 14.54 16.33 .33 .56 .95 .31
D6S259 D6S259 15.74 16.62 .49 1.16 1.60 .79
a244wf5 D6S1578 16.04 16.90 .56 1.33 1.78 .79
6p22.3 D6S260F D6S260 16.64 17.85 .67 1.60 2.22 .90
6p22.3 AFM321tc5 D6S1676 17.34 18.53 .64 1.55 2.08 .91
6p22.3 AFM189ye3 17.35 18.53 .64 1.56 2.08 .91
6p22.3 AFMb008wb5 D6S1605 18.05 18.76 .59 1.81 2.20 1.07
SCA1 (CAG) SCA1 18.25 18.77 .32 1.45 1.68 .98
SCA78a 18.35 18.78 .26 1.33 1.56 .90
D6S288 D6S288 18.36 18.84 .30 1.42 1.66 .96
a288zg9 D6S1584 19.16 19.16 .05 1.05 1.02 .43
TW9 19.17 19.18 .05 1.04 1.01 .38
D6S274L D6S274 19.18 19.20 .04 1.00 .99 .36
a219zd9 D6S1567 20.28 19.94 .00 .41 .56 .07
D6S285 D6S285 20.78 21.43 .01 1.01 1.15 .20
D6S422L D6S422 21.98 23.23 .00 1.12 1.55 .38
D6S299 D6S299 28.08 26.78 .01 .24 .68 .59
D6S276 D6S276 29.18 28.26 .01 .16 .57 .51
MFD61 D6S105 29.28 31.42 .01 .21 .65 .48
D6S273 D6S273 32.58 35.32 .07 .21 .78 .56
D6S291 D6S291 34.08 43.02 .04 .13 .52 .32
NOTE.—The two primary peaks are boxed.
a Chromosomal location in UCSC August 2001 draft assembly of the genome (see the UCSCHuman
Genome Project Working Draft Web site).
.08, and .08, respectively. With both the restricted data
set and aggregation of alleles having frequency 3%,
all four tests were negative. This LD finding in region
6p24.3 was not pursued further in the present study.
On the basis of these previously published linkage
results, we investigated region 6p22 in further detail,
by sequencing to find SNPs, genotyping, and analysis
using both case-control and family-based TDT designs.
We first concentrated on the 250-kb interval between
D6S1676 and the CAG repeat, in gene SCA1.We tested
a total of 34 SNPs in subsets of individuals (np 47–
), in an “internal case-control” design. The most300
highly selected group of cases (one per family) consisted
of affected individuals in categories D1–D2 who were
selected from those families that, during those separate
GENEHUNTER runs (results not shown), yielded pos-
itive H-LOD/NPL scores with the 16 SSLP mark-
ers in 6p23-22 (D6S1653–D6S422) but did not do so
with the adjacent set of 15 SSLP markers in 6p25-22
(D6S477–D6S443). The control group comprised un-
affected individuals who were unrelated (i.e., married-
in) to the affected individuals in their families and were
chosen from families that produced negative results
across the entire region. For these 34 SNPs, no sizable
or regionally consistent differences in allele frequencies
were observed (data not shown).
On the basis of these negative results, we then focused
on the 670-kb interval between D6S260 and D6S1676,
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Table 2
Markers and Map of 6p22
Gene (Exon Size)
Marker
(NCBI Numbera) Polymorphism Frequencyb
Chromosomal
Locationc
(Nucleotide Position)
Distance
from D6S260
(bp)
Size of
Interval
(bp)
Jumonji D6S260 SSLP NA 17854849–17855203 … …
P1730 (rs1474588) G/C .330 17912083 56,880 56,880
P1283 (rs760659) G/A .196 17954963 99,760 42,880
Dysbindin gene:d
Exon 10 (413 bp) 17973412–17973824
Exon 9 (144 bp) 17975131–17975274
P1328 (rs742106) C/T .376 17974854 119,651 19,891
Exon 8 (156 bp) 17983845–17984000
P1333 (rs742105) C/T .480 18023448 168,245 48,594
P1287 (rs760666) C/T .246 18039495 184,292 16,047
Exon 7 (23 bp) 18043664–18043686
Exon 6 (133 bp) 18065872–18066004
P1655 (rs2619539) G/C .537 18071229 216,026 31,734
Exon 5 (133 bp) 18077948–18078080
P1635 G/A .102 18078476 223,273 7,247
P1325 (rs1011313) T/C .088 18083806 228,603 5,330
Exon 4 (61 bp) 18088349–18088409
P1765 (rs2619528) A/G .167 18100203 245,000 16,397
P1757 (rs2005976) A/G .167 18101176 245,973 973
P1320 (rs760761) C/T .178 18101506 246,303 330
Exon 3 (51 bp) 18101918–18101968
Exon 2 (54 bp) 18102692–18102745
P1763 (rs2619522) C/A .155 18104023 248,820 2,517
P1578 (rs1018381) C/T .076 18107444 252,241 3,421
P1583 (rs909706) C/T .377 18111245 256,042 3,801
Exon 1 (160 bp) 18113419–18113578
Unknown P1586 (rs885773) A/G .093 18119860 264,657 8,615
P1294 (rs441539) A/G .380 18215012 359,809 95,152
P1140 (rs1000117) C/A .301 18324363 469,160 109,351
D6S1676 SSLP NA 18525332–18525609 670,406 201,246
AFM189YE3 SSLP NA 18534500–18534767 679,564 9,158
a Reference identification number for each SNP, from the dbSNP database (see the NCBI Single Nucleotide PolymorphismWeb
site).
b Of the second allele shown. NA p not applicable.
c From the UCSC August 2001 draft assembly of the genome (see the UCSC Human Genome Project Working Draft Web site).
d Exons and their genomic locations are based on transcript BC011912.
the two SSLPmarkers located atop the 6p22multipoint-
linkage peak. We identified SNPs by database searches
and by sequencing of pools of the highly selected cases.
Table 2 shows the map locations and marker char-
acteristics for the 3 SSLPs and 17 SNPs in 6p22 that were
tested in the entire sample. The markers are presented in
chromosomal order, with D6S260 telomeric. The first
three markers in the table are in the gene Jumonji, the
next 12 SNPs are in the geneDTNBP1 (i.e., the dysbindin
gene), and the next 5 markers are proximal to the dys-
bindin gene. Markers P1655, P1635, and P1765, as well
many others that we identified but did not test in the
entire sample, were first detected by sequencing of pools
of affected individuals, as described above. All SNPs
tested in dysbindin are intronic, except P1328, which is
in the 3′ UTR of transcript AL136637. Analysis using
multiple splice-site prediction programs (Mount 2000)
showed that none of the SNPs are predicted to affect
splicing, but this must be tested experimentally.
The pairwise TRANSMIT results are shown in table
3. When all individuals are included in the analysis, the
pattern of significance varies somewhat across diagnostic
categories, with maximal evidence for a given marker
usually occurring when either categories D1–D5 or cat-
egories D1–D8 are used. One clear exception to this pat-
tern, however, is SNP P1320. Except for the most cen-
tromeric marker, the SSLP AFM189YE3, the strongest
evidence was never found for the very-broad definition
(i.e., categories D1–D9), which includes psychiatric dis-
orders not considered to be within the schizophrenia
spectrum. When the analysis was restricted to one af-
fected offspring per nuclear family per extended pedi-
gree, the median P value of 20 runs was not significant
for markers P1333, P1655, P1325, markers that reached
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Table3
Pairwise TRANSMIT Results
GENE AND MARKER
(NCBI NUMBER)
OVERTRANSMITTED
ALLELE
(FREQUENCY)
TRANSMIT P VALUEa
All Individuals
One Affected Offspring per
Nuclear Family per Extended Pedigreeb
D1–D2 D1–D5 D1–D8 D1–D9 D1–D2 D1–D5 D1–D8 D1–D9
Jumonji:
D6S260 .193 .096 .018 .077 .579 .333 .341 .355
P1730 (rs1474588) .403 .743 .487 .187 .499 .242 .635 .605
P1283 (rs760659) .536 .797 .831 .411 .616 .535 .552 .626
Dysbindin:
P1328 (rs742106) .127 .125 .275 .256 .502 .332 .467 .436
P1333 (rs742105) T (.480) .0099 .0036 .0027 .019 .533 .507 .504 .559
P1287 (rs760666) .769 .603 .597 .954 .717 .638 .615 .578
P1655 (rs2619539) G (.463) .0059 .001 .0008 .014 .558 .504 .465 .544
P1635 A (.102) .00009 .00008 .00004 .024 .006 .0066 .027 .114
P1325 (rs1011313) C (.088) .174 .0377 .0104 .024 .562 .399 .512 .628
P1765 (rs2619528) G (.167) .109 .036 .095 .738 .0466 .171 .158 .561
P1757 (rs2005976) G (.167) .091 .037 .065 .960 .0078 .0366 .039 .157
P1320 (rs760761) T (.178) .0004 .020 .172 .929 .0029 .107 .127 .526
P1763 (rs2619522) A (.155) .202 .101 .130 .604 .0465 .229 .392 .677
P1578 (rs1018381) .762 .738 .488 .176 .473 .824 .553 .705
P1583 (rs909706) .969 .308 .299 .244 .282 .558 .645 .469
Unknown:
P1586 (rs885773) .478 .378 .226 .065 .293 .489 .495 .501
P1294 (rs441539) .018 .049 .051 .103 .071 .117 .146 .414
P1140 (rs1000117) .316 .137 .193 .078 .436 .604 .364 .604
D6S1676 .617 .359 .371 .354 .166 .218 .195 .090
AFM189YE3 .644 .086 .544 .036 .580 .695 .696 .623
a Generated by simulation.
b Median of 20 runs. Values !.05 are in boldface italic.
significance when all individuals were included. None of
the markers were positive when categories D1–D9 were
used. All of the markers in the entire sample were in
Hardy-Weinberg equilibrium. To test the possibility that
the positive TDT results were artifactual, due, in some
way, to transmission distortion, for P1635 we recoded
the affected individuals as unknown and the unaffected
individuals as affected. No transmission distortion was
observed.
We also analyzed two-, three-, and four-marker hap-
lotypes for the 17 SNPs and for the 2 flanking SSLPs.
Figure 1 shows the results, when diagnostic categories
D1–D2 were used, for all of the three-marker haplotypes
tested. The “global” P value represents the overall sig-
nificance when the observed versus expected transmis-
sions of all of the haplotypes are considered together.
Also shown are the most significant of the overtrans-
mitted haplotypes from that median run, the haplotype
frequency, and the associated P value. All of the adjacent,
overtransmitted three-marker haplotypes are consistent
with each other in terms of the SNP alleles represented.
Results with the two- and four-marker haplotypes (data
not shown) were also in quite good agreement with the
results for the pairwise and three-marker haplotypes.One
difference between the pairwise results and the haplotype
results occurred with marker P1325, for which the C
allele was slightly overtransmitted in all pairwise runs
but for which the T allele was contained in all three
overtransmitted three-marker haplotypes. The frequency
of themost positive haplotypes varied between 0.082 and
0.162, which is consistent with our previous estimates
based on linkage results—that !30% of the families seg-
regate susceptibility alleles on 6p.
Table 4 shows the pairwise marker-to-marker LD re-
sults; below the diagonal is the standard Lewontin D′
statistic, and above the diagonal is the d2 statistic. Note
the extremely strong LD (a) between P1333 and the 60-
kb region bounded by P1287 and P1325 and (b) with
the region bounded by P1578 and P1586, but not with
the markers between these two regions. In contrast, the
more proximal marker P1287 is in strong LD with the
entire 72-kb region bounded by P1655 and P1583. In
addition, P1325 is in strong LD with P1765 and P1757
(17 kb), is not at all in LD with P1320, and is “again”
in LD with P1763–P1294 (131 kb). With this complex
pattern of LD, neither the number of susceptibility al-
leles nor their specific location(s) is readily apparent.
Discussion
The picture emerging from detailed studies of the limited
number of genes that have been identified in complex
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Figure 1 TRANSMIT results with three-marker haplotypes. When diagnostic categories D1–D2 and the condition of one affected offspring
per nuclear family per extended pedigree are used, a sliding window of three markers was tested, at two-marker overlaps. Below each (most
significant) overtransmitted haplotype is the P value for that haplotype, the haplotype frequency, and the global P value (median value of 20
runs), derived by evaluation of the transmissions of all haplotypes at once. SNPs within the dysbindin gene are in boldface and are offset, and
the location of the gene is shown below the haplotype frequencies. Interval Length p marker-to-marker distance (in bp); na p instances in
which no individual haplotype (either over- or undertransmitted) resulted in .P ! .05
disorders is one of subtle, rather than striking, relation-
ships between genetic variation, gene function, and in-
creased risk (Risch 2000; Reich and Lander 2001). For
example, the role of specific SNPs in the calpain-10 gene
that are associated with type 2 diabetes is still unclear,
despite extensive efforts directed toward both SNP de-
tection and genotyping in multiple, large samples (Alt-
shuler et al. 2000a; Horikawa et al. 2000; Weiss and
Terwilliger 2000; Cox 2001; Evans et al. 2001). Another
example from type 2 diabetes is the frequent PPAR-g
Pro12Ala polymorphism, for which a meta-analysis of
13,000 individuals was necessary to resolve apparently
conflicting studies (Altshuler et al. 2000b). Likewise, de-
spite extensive efforts, the relationship between the se-
quence diversity in the APOE gene (Nickerson et al.
2000) and the contribution of this variation to the risk
of Alzheimer disease remains incompletely understood
(Daly 1998; Martin et al. 2000). Given these well-doc-
umented difficulties, the results presented here represent
only an initial step toward an understanding of the pos-
sible etiologic role that dysbindin plays in schizophrenia.
The complex pattern of positive versus negative TDT
results that we observed with individual markers may
indicate multiple susceptibility alleles (haplotypes), al-
though other explanations are possible; if true, this
would again support the expectation of a high degree
of allelic heterogeneity in most complex phenotypes
(Weiss and Terwilliger 2000). Nevertheless, the central
location of the positive SNPs within the 140-kb dysbin-
din gene strongly implicates this gene as a source of the
positive linkage signal in this chromosomal region. Our
results suggest that the susceptibility haplotypes prob-
ably do not extend distally to the neuronally expressed
gene Jumonji, which directly abuts the dysbindin gene
but is transcribed in the opposite direction. Proximally,
there are no ESTs or consistently predicted exons for the
next few hundred kilobases, but this certainly does not
rule out genes being present. It remains a formal pos-
sibility that dysbindin itself is not aberrant in schizo-
phrenia but, rather, that variations in it affect expression
of nearby genes; and this can be tested.
In view of the recent data showing the punctate, usu-
ally 10–100-kb haplotype block structure of the human
genome (Daly et al. 2001; Johnson et al. 2001; Reich
et al. 2001), confirmation that the dysbindin gene is the
sole susceptibility gene in this region may be relative-
ly straightforward, since the most strongly associated
markers and haplotypes reside within this gene. It does
appear that marker P1635, which we found by sequenc-
ing affected individuals from 6p22-linked families but
which other groups have not yet deposited into the pub-
lic databases, is an important boundary. In the pairwise
analysis, P1635 is strongly associated with schizophre-
nia, whereas the marker that is 5.3 kb proximal (i.e.,
marker P1325) is not. This boundary effect is also re-
flected in both the haplotype and the marker-to-marker
LD results. Although higher marker densities achieved
by use of the available (i.e., common) SNPs may be of
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Table 4
Pairwise (Marker-to-Marker) LD Results
PAIRWISE LD RESULTa
P1730 P1283 P1328 P1333 P1287 P1655 P1635 P1325 P1765 P1757 P1320 P1763 P1578 P1583 P1586 P1294 P1140
P1730 … .00 .16 .04 .10 .04 .02 .04 .03 .03 .01 .02 .14 .07 .08 .00 .02
P1283 .15 … .02 .00 .02 .00 .01 .13 .00 .00 .00 .01 .03 .00 .06 .00 .00
P1328 .45 .38 … .22 .05 .19 .00 .00 .02 .01 .00 .02 .01 .21 .01 .01 .00
P1333 .26 .00 .57 … .28 .81 .11 .09 .00 .00 .02 .00 .09 .54 .05 .05 .01
P1287 .79 .54 .49 .95 … .14 .38 .38 .36 .06 .06 .05 .03 .15 .01 .09 .00
P1655 .25 .07 .52 .93 1.00 … .10 .08 .01 .01 .02 .00 .05 .49 .03 .05 .00
P1635 .61 .53 .04 .96 1.00 .86 … .00 .36 .38 .46 .36 .12 .02 .00 .02 .01
P1325 .93 .58 .19 .94 .99 .94 .08 … .30 .28 .00 .30 .15 .14 .01 .05 .00
P1765 .28 .08 .37 .15 1.00 .17 .79 .99 … .92 .66 .87 .35 .09 .26 .03 .00
P1757 .29 .07 .34 .14 .94 .15 .82 .94 .96 … .70 .94 .38 .13 .23 .03 .00
P1320 .14 .06 .10 .28 .95 .26 .93 .00 .85 .87 … .69 .26 .04 .14 .04 .00
P1763 .25 .11 .38 .14 .99 .14 .76 1.00 .96 .99 .90 … .41 .49 .25 .04 .00
P1578 .93 .32 .45 .90 .95 .83 .87 1.00 .93 .97 .82 .97 … .07 .60 .01 .01
P1583 .29 .09 .47 .89 .86 .83 .51 .94 .83 .82 .54 .99 1.00 … .03 .02 .02
P1586 .61 .39 .37 .73 .52 .60 .22 .75 .71 .68 .56 .68 .85 .74 … .01 .01
P1294 .12 .04 .17 .30 .42 .30 .56 .90 .48 .53 .52 .62 .50 .20 .43 … .02
P1140 .17 .00 .07 .14 .16 .09 .38 .20 .01 .01 .07 .01 .22 .16 .22 .16 …
a For each pair of markers, the standardized D′ is shown below the diagonal, and d2 is shown above the diagonal. D′ values 10.8 are in
boldface italic.
some utility in finer mapping of the risk alleles, the
sobering findings from the haplotype-tagging study by
Todd and colleagues (Johnson et al. 2001) suggest that
the publicly available SNPs will be inadequate for “mu-
tation” detection, and so saturation resequencing in af-
fected individuals, starting near P1635, is necessary. The
SNPs tested are intronic, and, although none is located
in a canonical splice site, very little is known about the
function that specific intronic sequences have with re-
gard to hnRNA secondary structure, protein binding,
stability, and splicing efficiency. Thus, any of these as-
sociated SNPs may affect expression, and this possibility
has to be investigated directly by testing for differences
in transcript structures, quantity, and spatial and de-
velopmental distribution between patients and control
subjects.
Dysbindin is evolutionarily conserved and is predicted
to have a coiled-coil secondary structure (Burkhard et al.
2001) similar to that of the mouse ortholog (Dtnbp1)
(Benson et al. 2001), with which it exhibits a high degree
of protein-sequence identity. On the basis of EST align-
ments alone, there appear to be at least five alternative
transcripts.
In mouse brain, the dysbindin protein is found in
multiple anatomical locations, including axon fibers in
the corpus callosum, mossy-fiber terminal fields in the
hippocampus and cerebellum, and neuropil areas of the
neocortex, hippocampus, and substantia nigra (Benson
et al. 2001). Using semiquantitative PCR, we have
found that human dysbindin transcripts are expressed
in all 24 tissues (e.g., brain, heart, lung, etc.) tested, as
well as in all 12 brain regions (frontal lobe, temporal
lobe, cerebellum, hippocampus, substantia nigra, cau-
date nucleus, amygdala, thalamus, hypothalamus, pons,
medulla, and spinal cord) tested (data not shown).
Dysbindin binds to b-dystrobrevin and thus is like-
ly to also be a component of the dystrophin protein
complex (DPC) (Mehler 2000; Roberts 2001) found in
postsynaptic densities (PSD) (Blake et al. 1999) and else-
where in brain. In addition to its structural role in neu-
romuscular synapse formation and maintenance (Grady
et al. 2000), the DPC appears to be involved in signal
transduction—for example, by regulating nicotinic re-
ceptor clustering and by recruiting specific signaling
molecules such as neuronal nitric oxide synthase (Bredt
1999; Grady et al. 1999), an enzyme that also inter-
acts with PSD proteins (e.g., PSD-93 and PSD-95) that
are involved in N-methyl-D-aspartate–receptor cluster-
ing. The composition of the DPC in muscle and brain
(e.g., content of dystrophin isoforms Dp 427, Dp71,
and Dp140) differs and is also heterogeneous within
the brain (Moukhles and Carbonetto 2001), but it is
almost certain both to exert effects on synaptic function
in brain as well and to modulate other receptors. For
example, dystrophin is extensively colocalized with
postsynaptic gamma-aminobutyric acid (GABA-A)–re-
ceptor subtypes in hippocampus, cortex, and cerebellum
(Kneusel et al. 1999). Also, Kneusel et al. (1999) have
found that, in the mdx (dystrophin deficient) mouse
cerebellum and hippocampus, there was a marked re-
duction in the number (but not in the size) of synaptic
GABA-A–receptor clusters, whereas this was not true
for the striatum, which does not normally contain
dystrophin.
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The relationship between genomic variation in dys-
bindin and the biological processes involved in schi-
zophrenia is entirely speculative. Nevertheless, if dys-
bindin plays a role in synaptic signaling and plasticity,
it would be well positioned to play a pathogenic role.
There is abundant neuropathological evidence that syn-
aptic changes are associated with schizophrenia; for ex-
ample, both a reduced density of dendritic spines on the
excitatory pyramidal neurons and reductions in multi-
ple proteins found in afferent terminals in frontal cor-
tex and hippocampus have been reported (Weinber-
ger 1999; Glantz and Lewis 2001). Such changes suggest
reduced cortical connectivity and plasticity, which are
likely to be primary to the illness. Numerous as they
may be, genes coding for synaptic proteins, whether
functioning on dendritic spines presynaptically or post-
synaptically, are all tenable functional candidate genes
(Mirnics et al. 2001). In addition to the still rather dif-
fuse dopaminergic and developmental “hypotheses” of
schizophrenia, both the glutamatergic and GABA-ergic
systems have been implicated (Goldman-Rakic and Se-
lemon 1997; Benes 2000; Pearlson 2000), and these four
areas of investigation already overlap considerably. It
is conceivable that defects in dysbindin function could
affect more than one of these systems, during devel-
opment, adulthood, or both.
The intermediate (schizophrenia) phenotypes, of mod-
erately diminished premorbid IQ and related cognitive
measures (Elvevag and Goldberg 2000; Weickert et al.
2000), may be an interesting connection between the
function of the DPC in synaptic transmission and the
observed association between dysbindin and schizophre-
nia. The nonprogressive, cognitive deficits present in
Duchenne muscular dystrophy (DMD) and Becker mus-
cular dystrophy (BMD) are reflected in significantly low-
er IQ scores—approximately one-quarter of boys with
DMD (whose dystrophin is either missing entirely or
functionally mutant) are mildly mentally retarded (Blake
and Kroger 2000; Anderson et al. 2002). The impairment
is found to be greater on verbal than on nonverbal tests
(Moizard et al. 1998) and may be due to disruption of
DPC function during embryogenesis, although, as in the
case of schizophrenia, themajority of patients withDMD
exhibit neither gross nor histological brain abnormali-
ties. Since mutations in dysbindin may also compromise
DPC function, this may explain, at least in some small
measure, the well-known observation that the average
IQ of schizophrenics is lower than that in control sub-
jects. Overall, there appears to be little evidence of com-
orbidity between schizophrenia and the muscular dys-
trophies, but this alone would not preclude some overlap
in molecular mechanisms. Early reports had described (a)
a family in which four of five adult patients with BMD
also had schizophrenia or related disorders (Zatz et al.
1993) and, separately, (b) an association between schizo-
phrenia and DMD (Melo et al. 1993), but these results
may be anecdotal. Southern blotting of DNA from 94
schizophrenics was used to screen for deletions in exons
1–59 of dystrophin, but no deletions were identified (Lin-
dor et al. 1994). No SNP association studies have been
reported for dystrophin or other components of theDPC,
such as syntrophins, sarcoglycans, and dystroglycans.
A considerable amount of work will be required in
order to confirm and extend our findings of an associ-
ation between dysbindin and schizophrenia. At present,
the possibility that this is a false-positive result, due to
any of several possible artifacts, cannot, of course, be
formally ruled out. However, given the internal consis-
tency and strength of the results, we think that genetic
variation in dysbindin influences the risk of schizophrenia
and related schizophrenia-spectrum disorders and, thus,
that this gene should be the subject of further inquiry.
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